Teva Pharma (TEVA) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
RBC Capital Upgrades Teva Pharma (TEVA) to Outperform
November 3, 2014 8:09 AM ESTRBC Capital upgraded Teva Pharma (NYSE: TEVA) from Sector Perform to Outperform with a price target of $68.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $56.47 yesterday.
... MoreTeva Pharma (TEVA) Price Target Raised to $64 at Deutsche Bank
October 30, 2014 2:00 PM EDTDeutsche Bank maintained a Buy rating on Teva Pharma (NYSE: TEVA) and raised its price target to $64.00 (from $63.00). The change follows solid Q3 results.
Analyst Gregg Gilbert said, "We updated our model following TEVAs 3Q results, which were notable for significant... More
